Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

P. Razavi, K. A. Rand, W. Cozen, Asher A Chanan Khan, S. Usmani, Sikander Ailawadhi

Research output: Contribution to journalArticle

32 Citations (Scopus)

Abstract

Recent studies have reported an increased risk of second primary malignancies (SPM) following multiple myeloma (MM) diagnosis associated with novel anti-myeloma treatments. We evaluated the risk of SPM among 36 491 MM cases reported to the Surveillance, Epidemiology, and End Results program (SEER) between 1973 and 2008. We calculated overall and site-specific standardized incidence ratio (SIR) and 95% confidence intervals (CI) for 2012 SPM cases diagnosed within the 35-year follow-up. There was no significant overall risk of SPM (SIR=0.98; 95% CI=0.94-1.02); however, there were multiple site-specific risk patterns. The risk of breast and prostate cancer was significantly decreased overall and across age, latency and the year of diagnosis strata. There was an ∼50% increased risk of colorectal cancer 5 years after MM diagnosis (Ptrend<0.001). The risk of hematological malignancies was significantly increased, notably for acute myeloid leukemia (AML; SIR=6.51; 95% CI=5.42-7.83). There was a significant decreasing trend for AML over time, particularly for patients ≥65. However, no significant change in risk was noted after the introduction of autologous stem cell transplant among younger patients (<65 years). On the basis of observed trends for overall SPM as well as AML, no association between the introduction of novel therapies and SPM following MM has emerged in this large population-based study.

Original languageEnglish (US)
Article numbere121
JournalBlood Cancer Journal
Volume3
Issue number6
DOIs
StatePublished - Jun 2013

Fingerprint

Second Primary Neoplasms
Multiple Myeloma
Confidence Intervals
Therapeutics
Incidence
SEER Program
Hematologic Neoplasms
Acute Myeloid Leukemia
Colorectal Neoplasms
Prostatic Neoplasms
Stem Cells
Breast Neoplasms
Transplants

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics. / Razavi, P.; Rand, K. A.; Cozen, W.; Chanan Khan, Asher A; Usmani, S.; Ailawadhi, Sikander.

In: Blood Cancer Journal, Vol. 3, No. 6, e121, 06.2013.

Research output: Contribution to journalArticle

@article{26e825cb8b1e404f9b4903c6a12f6cc1,
title = "Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics",
abstract = "Recent studies have reported an increased risk of second primary malignancies (SPM) following multiple myeloma (MM) diagnosis associated with novel anti-myeloma treatments. We evaluated the risk of SPM among 36 491 MM cases reported to the Surveillance, Epidemiology, and End Results program (SEER) between 1973 and 2008. We calculated overall and site-specific standardized incidence ratio (SIR) and 95{\%} confidence intervals (CI) for 2012 SPM cases diagnosed within the 35-year follow-up. There was no significant overall risk of SPM (SIR=0.98; 95{\%} CI=0.94-1.02); however, there were multiple site-specific risk patterns. The risk of breast and prostate cancer was significantly decreased overall and across age, latency and the year of diagnosis strata. There was an ∼50{\%} increased risk of colorectal cancer 5 years after MM diagnosis (Ptrend<0.001). The risk of hematological malignancies was significantly increased, notably for acute myeloid leukemia (AML; SIR=6.51; 95{\%} CI=5.42-7.83). There was a significant decreasing trend for AML over time, particularly for patients ≥65. However, no significant change in risk was noted after the introduction of autologous stem cell transplant among younger patients (<65 years). On the basis of observed trends for overall SPM as well as AML, no association between the introduction of novel therapies and SPM following MM has emerged in this large population-based study.",
author = "P. Razavi and Rand, {K. A.} and W. Cozen and {Chanan Khan}, {Asher A} and S. Usmani and Sikander Ailawadhi",
year = "2013",
month = "6",
doi = "10.1038/bcj.2013.19",
language = "English (US)",
volume = "3",
journal = "Blood Cancer Journal",
issn = "2044-5385",
publisher = "Nature Publishing Group",
number = "6",

}

TY - JOUR

T1 - Patterns of second primary malignancy risk in multiple myeloma patients before and after the introduction of novel therapeutics

AU - Razavi, P.

AU - Rand, K. A.

AU - Cozen, W.

AU - Chanan Khan, Asher A

AU - Usmani, S.

AU - Ailawadhi, Sikander

PY - 2013/6

Y1 - 2013/6

N2 - Recent studies have reported an increased risk of second primary malignancies (SPM) following multiple myeloma (MM) diagnosis associated with novel anti-myeloma treatments. We evaluated the risk of SPM among 36 491 MM cases reported to the Surveillance, Epidemiology, and End Results program (SEER) between 1973 and 2008. We calculated overall and site-specific standardized incidence ratio (SIR) and 95% confidence intervals (CI) for 2012 SPM cases diagnosed within the 35-year follow-up. There was no significant overall risk of SPM (SIR=0.98; 95% CI=0.94-1.02); however, there were multiple site-specific risk patterns. The risk of breast and prostate cancer was significantly decreased overall and across age, latency and the year of diagnosis strata. There was an ∼50% increased risk of colorectal cancer 5 years after MM diagnosis (Ptrend<0.001). The risk of hematological malignancies was significantly increased, notably for acute myeloid leukemia (AML; SIR=6.51; 95% CI=5.42-7.83). There was a significant decreasing trend for AML over time, particularly for patients ≥65. However, no significant change in risk was noted after the introduction of autologous stem cell transplant among younger patients (<65 years). On the basis of observed trends for overall SPM as well as AML, no association between the introduction of novel therapies and SPM following MM has emerged in this large population-based study.

AB - Recent studies have reported an increased risk of second primary malignancies (SPM) following multiple myeloma (MM) diagnosis associated with novel anti-myeloma treatments. We evaluated the risk of SPM among 36 491 MM cases reported to the Surveillance, Epidemiology, and End Results program (SEER) between 1973 and 2008. We calculated overall and site-specific standardized incidence ratio (SIR) and 95% confidence intervals (CI) for 2012 SPM cases diagnosed within the 35-year follow-up. There was no significant overall risk of SPM (SIR=0.98; 95% CI=0.94-1.02); however, there were multiple site-specific risk patterns. The risk of breast and prostate cancer was significantly decreased overall and across age, latency and the year of diagnosis strata. There was an ∼50% increased risk of colorectal cancer 5 years after MM diagnosis (Ptrend<0.001). The risk of hematological malignancies was significantly increased, notably for acute myeloid leukemia (AML; SIR=6.51; 95% CI=5.42-7.83). There was a significant decreasing trend for AML over time, particularly for patients ≥65. However, no significant change in risk was noted after the introduction of autologous stem cell transplant among younger patients (<65 years). On the basis of observed trends for overall SPM as well as AML, no association between the introduction of novel therapies and SPM following MM has emerged in this large population-based study.

UR - http://www.scopus.com/inward/record.url?scp=84880854828&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84880854828&partnerID=8YFLogxK

U2 - 10.1038/bcj.2013.19

DO - 10.1038/bcj.2013.19

M3 - Article

C2 - 23811785

AN - SCOPUS:84880854828

VL - 3

JO - Blood Cancer Journal

JF - Blood Cancer Journal

SN - 2044-5385

IS - 6

M1 - e121

ER -